Drug Profile
AR 623
Alternative Names: All-trans-retinoic acid; ATRA-IV; Atragen; LipoATRA; Tretinoin LF; Tretinoin liposomalLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Antigenics
- Developer Agenus; Antigenics
- Class Antineoplastics; Keratolytics; Retinoids
- Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Bladder cancer; Cancer; Kaposi's sarcoma; Non-Hodgkin's lymphoma; Prostate cancer; Renal cancer
Most Recent Events
- 06 Jan 2011 Antigenics is now called Agenus
- 04 Oct 2006 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
- 04 Oct 2006 Discontinued - Phase-II for Acute promyelocytic leukaemia in USA (IV)